Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aquestive Therapeutics (AQST)
NASDAQ:AQST
RESEARCH TOOLSreports
Aquestive Therapeutics (AQST) Stock Price & Analysis
1,934 Followers
AQST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.25 - $6.23
Previous Close$2.48
Volume1.15M
Average Volume (3M)1.89M
Market Cap
$225.78M
Enterprise Value$259.09M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$33.32M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Aug 06, 2024EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding91,038,532
10 Day Avg. Volume1,351,001
30 Day Avg. Volume1,890,182
Standard Deviation0.33
R-Squared0.20
Alpha0.00760
Financial Highlights & Ratios
Price to Book (P/B)-2.16
Price to Sales (P/S)17.65
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue5.12
Enterprise Value/Gross Profit8.71
Enterprise Value/Ebitda217.00
Forecast
1Y Price Target
$8.92Price Target Upside259.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Aquestive Therapeutics News
PremiumCompany Announcements
Aquestive Therapeutics Shares Investor Presentation Update
PremiumCompany Announcements
Aquestive Therapeutics Appoints Cassie Jung as COO
Bulls Say, Bears Say
Bulls Say
Market PotentialThe epinephrine market is expanding as severe Type I allergy reactions increase, with strong demand for convenient, no-needle options for severe allergy attacks.
Product InnovationAnaphylm™ could be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the FDA.
Regulatory ProgressFeedback from a recent Type C meeting with FDA reinforces confidence in the company's clear alignment with the agency on the path to approval.
Bears Say
CompetitionCompetitor product candidate resubmitted to FDA could enjoy a lead time of around 12 months versus Anaphylm.
Equity FinancingAnalyst lowers risk-adjusted, DCF-derived price target for Aquestive Therapeutics to $9 from $10, reflecting the recent equity financing.
Financial PerformanceThe company recorded a higher net loss per share than forecasted due to non-recurring items and higher-than-anticipated expenses.
---
Ownership Overview
7.28% Insiders
5.37% Mutual Funds
34.55% Other Institutional Investors
52.80% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AQST FAQ
What was Aquestive Therapeutics’s price range in the past 12 months?
Aquestive Therapeutics lowest stock price was $1.25 and its highest was $6.23 in the past 12 months.
What is Aquestive Therapeutics’s market cap?
Currently, no data Available
When is Aquestive Therapeutics’s upcoming earnings report date?
Aquestive Therapeutics’s upcoming earnings report date is Aug 06, 2024 which is in 30 days.
How were Aquestive Therapeutics’s earnings last quarter?
Aquestive Therapeutics released its earnings results on May 07, 2024. The company reported -$0.17 earnings per share for the quarter, missing the consensus estimate of -$0.089 by -$0.081.
Is Aquestive Therapeutics overvalued?
According to Wall Street analysts Aquestive Therapeutics’s price is currently Undervalued.
Does Aquestive Therapeutics pay dividends?
Aquestive Therapeutics does not currently pay dividends.
What is Aquestive Therapeutics’s EPS estimate?
Aquestive Therapeutics’s EPS estimate is -$0.12.
How many shares outstanding does Aquestive Therapeutics have?
Aquestive Therapeutics has 91,038,530 shares outstanding.
What happened to Aquestive Therapeutics’s price movement after its last earnings report?
Aquestive Therapeutics reported an EPS of -$0.17 in its last earnings report, missing expectations of -$0.089. Following the earnings report the stock price went down -8.876%.
Which hedge fund is a major shareholder of Aquestive Therapeutics?
Among the largest hedge funds holding Aquestive Therapeutics’s share is Woodline Partners LP. It holds Aquestive Therapeutics’s shares valued at 3M.
---
Aquestive Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.92 (259.68% Upside)
$8.92 (259.68% Upside)
Blogger Sentiment
Bullish
AQST Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 600.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
49.39%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
111.35%
Trailing 12-Months
Company Description
Aquestive Therapeutics
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm® technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.
---
AQST Company Deck
---
AQST Earnings Call
Q1 2024
0:00 / 0:00
---
AQST Stock 12 Month Forecast
Average Price Target
$8.92
▲(259.68% Upside)
Technical Analysis
Best Analysts Covering AQST
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+35.79%
reiterated a buy rating last month
Copying Ram Selvaraju's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +35.79% per trade.
---